Everyone

Michael Pehl, MSc

CEO, Adcendo

Michael serves as our Chief Executive Officer and a Board Director. Michael brings ample leadership experience from global pharmaceutical and biotechnology companies, having led multiple marketed hematology & oncology products through development and commercialization, including Revlimid®, Vidaza®, Trodelvy®, Abraxane® and Reblozyl®. Among his many roles, Michael served as Chief Executive Officer of Immunomedics, Inc. and President of Hematology & Oncology of Celgene Corporation.

John Doe, PhD

CSO

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Carmel M. Lynch, PhD

Chief Development Officer

+25 years of experience in biotechnology, spanning from discovery research to clinical development, with an emphasis on translational medicine. +15 years specializing in ADCs; led Nonclinical and Clinical Pharmacology development of Adcetris ADC at SeaGen from pre-IND to approval in 2011

Pernille Hemmingsen, PhD

Chief Technology Officer

Pernille serves as our Chief Technology Officer and is responsible for CMC and global supply at Adcendo. Pernille brings over 20 years of technical operations experience in the pharmaceutical industry. Prior to joining Adcendo, Pernille served as VP of Global Product Development and Supply at Savara ApS, as well as led the Tivdak® CMC program from non-clinical through late-stage development at Genmab A/S.

Christoffer Nielsen, PhD

VP Operations, General Manager & Co-founder

Christoffer (Chris) co-founded Adcendo ApS and serves as our VP Operations and General Manger, responsible for our day-to-day operations and associated functions. Christoffer brings more than 15 years of scientific and management experience, ranging from early discovery of our programs to operational management roles at Adcendo